Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Plenty mileage in the share price yet. I cannot fathom why people would sell as its very evident there is significant value to come with Exscientia.
Thanks for the info. I also believe that Exscientia could be worth the Mcap alone in a reasonably short period of time.
Exscientia was the main reason I bought into Fipp.It’s not clear what our percentage stake in Exscientia will now be after this latest funding round. However even if we are down to 1%, I still believe that stake could be worth more than the current market cap of Fipp.
A couple of years ago it was thought Exscientia would list on Nasdaq with $1bn valuation. I suspect that if and when they do decide to go down that route it will attract a valuation a few multiples of that.
FIPP use last funding event for valuation, so nav will lag either an up round or down round. If Exscientia's last round was done at $1bn valuation (not unreasonable to assume looking at the sums raised) and FIPP have 2% after dilution that will be a massive uplift to their old book value. We will just have to wait for the figures, but that is why they had to make today's statement. I think the last brokers note had £1 either as nav or target price.
Looks like excscientia could make quite a difference even though it’s just over 2%. Could be huge.
An interesting stock. It looks like it’s price is double it’s NAV. I know holdings are often undervalued but double ? Any long term holders here that have any info.
I'm kicking myself for not buying in at 62p when I had the chance. Was a little worried at the time about potential dilution as administrative costs are being paid for out of fairly regular share offerings. Should have just jumped in though, I'd be up more than a third already if I had!
Do we think this is near the top of the price range for now? Or merely the beginning of an upward revaluation of the portfolio?
My brother who is a biotech fan got me into this stock.
He thesis was portfolio particularly Exscietifica was undervalued looks like he was correct.
Should have invested more
Might top up today
And still dropping buy on any weakness and dips
dyor
Really good progress, huge increase in portfolio value and unrealised profit.
Perhaps a large entity sold some shares? Can't see any reason this should be selling off.
Not much, which is a bit of a surprise. Having said that I'm not sure what the market is doing today.
Agreed!
with the progress made they look well undervalued but I wonder what Mr Market makes of them?
Strong results with the added message that they look forward to reporting further developments on Exscientia. Only a matter of time before it lists on the Nasdaq.
No surprise the share price is going in this direction. Roll on Wednesday
Looking for positive news on the investee companies on Wednesday that should provide an uplift in the portfolio valuation.
I am a new investor in this company having taken time to look at their investee companies which I am quite impressed with. - I have also listened to the CEO interviews. It looks clear to me that the sum of the parts could be much higher than the current valuation of FIPP on any disposals but by how much I have no idea. I do wonder however if they will need to sell some of the interests in order to save any heavy dilution should one of the investee companies need further funding. If I understood what the CEO said in his more recent interview the 24 March could provide an interesting update.
Biotechboy you have bought in towards what has been the average price over the last 12 months so a good entry point. My first purchase was I think around 72p early last year but with subsequent purchases I am averaging around 63pish in the SIPP.
With markets talking about overvalued tech we unfairly fall when the Nasdaq suffers big. But although there is a tech and health focus our valuations are at the conservative book values so if anything we are a bargain buy - think we may have been in Simon Thompson's bargain portfolio? So we are not overvalued tech but fall more within the "value" type investments that value investors look for.
As you say diversification is built in and a number of the businesses are getting to a decent size now. Should be exciting times ahead and good growth from now to the the next few years and beyond. Also a quality management team.
I entirely agree with the last 4 posts. I've been involved with biotech for a professional lifetime. IMO Simon Thompson's recent justifiably detailed analysis of this company's biotech portfolio is spot-on, in spelling out both the significant potential of these holdings and their underestimated value. I'm in today, wish I'd spotted it earlier and intend to build a position over time; diversification is built-in reducing the risk for the small investor. The ability to commercialise means everything in this field; a really good proposition for the medium-long term IMO.
Quality stock. One to just lock away for a few years I reckon. Also interesting with this one compared to other similar investment type companies is the partnerships being entered into with each investee company and/or the external funding from outside investors. With a lot of investment type companies it is the vct or investment company that provides a lot of the ongoing funding. To get external funding is another validation of the tech.
Lol good news coming?
Good news has been coming out year after year, and almost month after month.
This share is criminally undervalued. The market just takes time to recognise micro caps. But when they do, hold on to your butts.
Congratulations - have a good day
It’s a no brainer
Simon Thompson tipped it at 5pm on Friday.
I bought in Friday morning at 61.5 and after Friday closing (57.5) I thought it was a really bad timing. But today it has started to fly. Good news coming?
What a surprise. Expect this to go places prior to the 24th.